Allopurinol-induced pyrimidinuria in cancer patients

Michael A Carducci, Michael Choti, Nancy E. Maestri, Saul W. Brusilow

Research output: Contribution to journalArticle

Abstract

Allopurinol induced pyrimidinuria is a sensitive and specific test that identifies the increased de novo pyrimidine mononucleotide biosynthesis accompanying ornithine trans carbamylase deficiency. We hypothesize that the increased de novo DNA synthesis characteristic of malignant tumors can be detected using this method. Eleven cancer patients and a 30 subject control group were studied. The allopurinol test protocol consists of five urine collection periods - a baseline collection after which time a 300 mg dose of allopurinol is taken, followed by collection of four 6 hour fractional urine collections. Orotate, orotidine and creatinine were measured on the samples. Eight of 11 patients had significantly elevated urine levels of either orotate or orotidine either prior to challenge with allopurinol or during one of the time periods. The allopurinol test for this unstratified group has a sensitivity of 0.73 and a specificity of 1.0. This observational and preliminary report suggest that further study of the potential significance and usefulness of the allopurinol test in patients at risk for or with malignancy is warranted.

Original languageEnglish (US)
Pages (from-to)271-274
Number of pages4
JournalIn vivo (Athens, Greece)
Volume12
Issue number3
StatePublished - May 1998

Fingerprint

Allopurinol
Neoplasms
Urine Specimen Collection
Ornithine
Biosynthesis
Tumors
Creatinine
Urine
Control Groups
DNA

Keywords

  • Allopurinol
  • Cancer patients
  • Pyrimidinuria

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Carducci, M. A., Choti, M., Maestri, N. E., & Brusilow, S. W. (1998). Allopurinol-induced pyrimidinuria in cancer patients. In vivo (Athens, Greece), 12(3), 271-274.

Allopurinol-induced pyrimidinuria in cancer patients. / Carducci, Michael A; Choti, Michael; Maestri, Nancy E.; Brusilow, Saul W.

In: In vivo (Athens, Greece), Vol. 12, No. 3, 05.1998, p. 271-274.

Research output: Contribution to journalArticle

Carducci, MA, Choti, M, Maestri, NE & Brusilow, SW 1998, 'Allopurinol-induced pyrimidinuria in cancer patients', In vivo (Athens, Greece), vol. 12, no. 3, pp. 271-274.
Carducci MA, Choti M, Maestri NE, Brusilow SW. Allopurinol-induced pyrimidinuria in cancer patients. In vivo (Athens, Greece). 1998 May;12(3):271-274.
Carducci, Michael A ; Choti, Michael ; Maestri, Nancy E. ; Brusilow, Saul W. / Allopurinol-induced pyrimidinuria in cancer patients. In: In vivo (Athens, Greece). 1998 ; Vol. 12, No. 3. pp. 271-274.
@article{9ef62cc236b64d0bbc666878f75de459,
title = "Allopurinol-induced pyrimidinuria in cancer patients",
abstract = "Allopurinol induced pyrimidinuria is a sensitive and specific test that identifies the increased de novo pyrimidine mononucleotide biosynthesis accompanying ornithine trans carbamylase deficiency. We hypothesize that the increased de novo DNA synthesis characteristic of malignant tumors can be detected using this method. Eleven cancer patients and a 30 subject control group were studied. The allopurinol test protocol consists of five urine collection periods - a baseline collection after which time a 300 mg dose of allopurinol is taken, followed by collection of four 6 hour fractional urine collections. Orotate, orotidine and creatinine were measured on the samples. Eight of 11 patients had significantly elevated urine levels of either orotate or orotidine either prior to challenge with allopurinol or during one of the time periods. The allopurinol test for this unstratified group has a sensitivity of 0.73 and a specificity of 1.0. This observational and preliminary report suggest that further study of the potential significance and usefulness of the allopurinol test in patients at risk for or with malignancy is warranted.",
keywords = "Allopurinol, Cancer patients, Pyrimidinuria",
author = "Carducci, {Michael A} and Michael Choti and Maestri, {Nancy E.} and Brusilow, {Saul W.}",
year = "1998",
month = "5",
language = "English (US)",
volume = "12",
pages = "271--274",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Allopurinol-induced pyrimidinuria in cancer patients

AU - Carducci, Michael A

AU - Choti, Michael

AU - Maestri, Nancy E.

AU - Brusilow, Saul W.

PY - 1998/5

Y1 - 1998/5

N2 - Allopurinol induced pyrimidinuria is a sensitive and specific test that identifies the increased de novo pyrimidine mononucleotide biosynthesis accompanying ornithine trans carbamylase deficiency. We hypothesize that the increased de novo DNA synthesis characteristic of malignant tumors can be detected using this method. Eleven cancer patients and a 30 subject control group were studied. The allopurinol test protocol consists of five urine collection periods - a baseline collection after which time a 300 mg dose of allopurinol is taken, followed by collection of four 6 hour fractional urine collections. Orotate, orotidine and creatinine were measured on the samples. Eight of 11 patients had significantly elevated urine levels of either orotate or orotidine either prior to challenge with allopurinol or during one of the time periods. The allopurinol test for this unstratified group has a sensitivity of 0.73 and a specificity of 1.0. This observational and preliminary report suggest that further study of the potential significance and usefulness of the allopurinol test in patients at risk for or with malignancy is warranted.

AB - Allopurinol induced pyrimidinuria is a sensitive and specific test that identifies the increased de novo pyrimidine mononucleotide biosynthesis accompanying ornithine trans carbamylase deficiency. We hypothesize that the increased de novo DNA synthesis characteristic of malignant tumors can be detected using this method. Eleven cancer patients and a 30 subject control group were studied. The allopurinol test protocol consists of five urine collection periods - a baseline collection after which time a 300 mg dose of allopurinol is taken, followed by collection of four 6 hour fractional urine collections. Orotate, orotidine and creatinine were measured on the samples. Eight of 11 patients had significantly elevated urine levels of either orotate or orotidine either prior to challenge with allopurinol or during one of the time periods. The allopurinol test for this unstratified group has a sensitivity of 0.73 and a specificity of 1.0. This observational and preliminary report suggest that further study of the potential significance and usefulness of the allopurinol test in patients at risk for or with malignancy is warranted.

KW - Allopurinol

KW - Cancer patients

KW - Pyrimidinuria

UR - http://www.scopus.com/inward/record.url?scp=0031825371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031825371&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 271

EP - 274

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 3

ER -